Elan, Neurome deal

Neurome will use ELN's amyloid deposition mouse model of Alzheimer's disease to identify molecules and pathways to treat and diagnose the disease. Neurome will receive up to $4 million in service revenue and will share ownership of the diagnostic and therapeutic applications with ELN. ...